Smith & Nephew Stock Price, News & Analysis

Smith+Nephew (NYSE:SNN) has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel treatment for chronic wounds. The system, which uses a patient's own platelets and plasma, is designed for managing various wound types including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

The CENTRIO PRP System is supported by two randomized controlled clinical trials and has received CMS coverage for treating chronic non-healing wounds in diabetic patients. The system can be used in both hospital and physician office settings, with the gel being customizable to fit different wound characteristics using a single blood draw.

Smith+Nephew has entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc. to market the system in the United States.

Smith+Nephew (NYSE:SNN) has announced the launch of its Q-FIX KNOTLESS All-Suture Anchor, expanding its portfolio for soft tissue-to-bone fixation across shoulder, hip, and foot & ankle applications. The new product builds upon the company's successful Q-FIX Family line, offering market-leading fixation strength and ultra-low displacement compared to competitive devices.

Key features include consistent deployment, best-in-class soft tissue security with a suture lock mechanism, and streamlined suture shuttling. The anchor comes with versatile suture options, including single-loaded MINITAPE Suture Tape and ULTRABRAID #2 Suture, which is 20% stronger than its nearest competitor.

Smith+Nephew (NYSE:SNN) has announced its continued sponsorship of select players during The Championships, Wimbledon 2025, showcasing its advanced Sports Medicine solutions for joint repair. Following their successful 2024 sponsorship, which included supporting Jasmine Paolini through to the Ladies Final, the company aims to highlight their innovative medical technology portfolio.

The company is featuring three key products: the REGENETEN Bioinductive Implant for rotator cuff repairs, which has been used in over 150,000 procedures globally since 2014; the CARTIHEAL AGILI-C Cartilage Repair Implant for knee cartilage and osteochondral defects; and the Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation.

The REGENETEN implant has demonstrated lower re-tear rates compared to conventional techniques and is backed by level one clinical evidence. The CARTIHEAL implant has shown meaningful improvements in pain, function, and quality of life, while the Q-FIX KNOTLESS anchor aims to set new benchmarks for soft tissue security.

Smith+Nephew (NYSE:SNN) has launched its new TRIGEN MAX Tibia Nailing System for treating tibial fractures. This innovative system is the first to offer side-specific nails for anatomic screw trajectories, optimizing fragment fixation and minimizing soft tissue irritation. The system features a two-piece modular drop system, 12.5mm channel reamer, and 5.0mm Lag Screws for streamlined workflow.

Building on the proven performance of TRIGEN Nails over two decades, the new system represents a significant advancement in lower extremity trauma care. The first case using the TRIGEN MAX system has been completed, and it is currently available exclusively in the United States.

Smith+Nephew (NYSE:SNN) has appointed Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective June 23, 2025. Dhankhar brings 25 years of experience from McKinsey & Company, where he served as Senior Partner and held key positions including Global Head of Strategy and M&A for Life Sciences. He later worked at Lazard Ltd as Managing Director and Global Head of Medical Technology, Diagnostics and Tools. Most recently, he founded Bluish Capital, focusing on growth capital deployment for FDA-approved assets. Dhankhar holds bachelor's degrees in Physics and Computer Science, along with a master's and doctorate in Molecular Biophysics and Biochemistry from Yale University. He will report to CEO Deepak Nath and join the Executive Committee.

Smith+Nephew (NYSE:SNN) has partnered with Standard Health to establish the UK's first Orthopaedic Ambulatory Surgery Centre in Poole, Dorset. The facility will provide both NHS and private patients with access to advanced joint repair and replacement procedures. Standard Health plans to expand to 10 additional UK sites within three years and reach 20 locations by 2030. The center will follow the successful US ASC model, where such facilities show 92% patient satisfaction rates and 40% cost reduction compared to hospital-based surgeries. Set to open in 2025, the Poole facility will serve thousands of patients annually, primarily NHS referrals, helping address the current backlog of over 850,000 people awaiting orthopaedic surgery in the UK. Smith+Nephew will supply its medical technology portfolio while Standard Health manages site development and operations.

Smith+Nephew (NYSE:SNN) has introduced a new medial stabilized insert for its LEGION Total Knee System. The innovation comes as medial stabilized inserts have seen significant growth, increasing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. The new design features a larger anterior medial lip and medial pivot kinematics to maintain stability, similar to natural knee movement. The system can be used with or without the Posterior Cruciate Ligament, offering greater procedural efficiency and potentially reducing operating time. The LEGION TKS has over 20 years of clinical success, and this new insert supports both LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The product is currently available in the US on a limited basis, with full commercial release planned for later in 2025 and Canadian introduction in 2026.

Smith+Nephew (NYSE:SNN) has secured a significant $75 million contract with the U.S. Department of Defense to provide RENASYS TOUCH Negative Pressure Wound Therapy Systems. The 10-year contract (5 years plus 5 one-year options) was awarded through the Defense Logistics Agency. The RENASYS TOUCH NPWT System, manufactured in the United States, was selected for its clinical efficacy, portability, and intuitive interface. The system will support military medical providers across various care settings, from casualty care to military treatment facilities. This contract builds upon Smith+Nephew's 2024 Master Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research, continuing the company's century-long tradition of supporting military medical needs.

Smith+Nephew (NYSE:SNN) has released findings from a large comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in C-section recovery. The study, analyzing over 10,000 C-section patients, demonstrates that PICO sNPWT significantly reduces surgical site complications and delivers substantial cost savings of $728,220 per 1,000 patients compared to other sNPWT devices. The research shows significant reductions in surgical site infections (SSIs), wound dehiscence, and seroma formation. A complementary survey revealed that mothers with complications were 5 times more likely to describe their recovery as traumatic, with 55% reporting depression. The study is particularly relevant as C-sections account for 32% of US births, with 44.6% considered high-risk, and SSIs alone cost over $900 million annually.